drugset / Trial / NCT00000826
Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites
Open-labelTreatment
Summary
To determine the effects of fluconazole and either rifabutin or clarithromycin, alone and in combination, on the pharmacokinetics of first sulfamethoxazole-trimethoprim and then dapsone in HIV-infected patients. Although prophylaxis for more than one opportunistic infection is emerging as a common clinical practice in patients with advanced HIV disease, little is known about possible adverse drug interactions. The need exists to define pharmacokinetics and pharmacodynamic adverse interactions of the many combination prophylactic regimens that may be prescribed.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 1999-05
Publications
- Background Cheng B. Preventing opportunistic infections. PI Perspect. 1995 May;(no 16):14-5.
- Results Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, Unadkat JD. The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). Clin Pharmacol Ther. 2004 Oct;76(4):313-22. doi: 10.1016/j.clpt.2004.06.002.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Dapsone | Small molecule | — | — |
| Subject | Fluconazole | Small molecule | 200 mg | — |
| Subject | Rifabutin | Small molecule | 300 mg | — |
| Subject | trimethoprim-sulfamethoxazole | Unknown | 160 mg | — |
| Subject | trimethoprim-sulfamethoxazole | Unknown | 800 mg | — |